Lin Shen

Research interests

Publications

• Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

  JAMA · 2023 · https://doi.org/10.1001/jama.2023.19918

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

  Cancer Cell · 2022 · https://doi.org/10.1016/j.ccell.2022.02.007

• Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

  Nature · 2022 · https://doi.org/10.1038/s41586-022-04508-4

• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Nature · 2021 · https://doi.org/10.1038/s41586-021-04161-3

• Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)01234-4

• 3D printing of conducting polymers

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-15316-7

• The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

  癌症：英文版 · 2019 · https://doi.org/10.1186/s40880-019-0349-9

• Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz197

• Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30682-4

Current projects

No projects listed.